TheraRadar
← Back
Data updated: May 24, 2026

GALDERMA LABS

Pharma
DermatologyImmunology Execution: Excellent

GALDERMA LABS is a pharmaceutical company focused on Dermatology, Immunology. Key products include EPIDUO FORTE.

2004
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

GALDERMA LABS at a Glance

  • Strong track record with 92% execution quality across 149 trials
  • Leading 5 drug targets across portfolio

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

EPIDUO FORTE
Dermatology

Acne Vulgaris

Retinoic acid receptor Approved 2015

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Dermatology 67%
2 drugs
Immunology 33%
1 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • EPIDUO FORTE leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Dermatology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 44/49 completed
  • • Speed: 10 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges